| Mr Terry K Brooks, NP-C | |
|
40 Monmouth Rd, Oakhurst, NJ 07755-1654 | |
| (732) 263-1220 | |
| (732) 229-2235 |
| Full Name | Mr Terry K Brooks |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 40 Monmouth Rd, Oakhurst, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013257740 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WC0200X | Registered Nurse - Critical Care Medicine | 26NO10663300 (New Jersey) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 26NJ00452500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayada Home Health Care, Inc | Whiting, NJ | Home health agency |
| Vna Of Central Jersey Home Care & Hospice | Toms river, NJ | Home health agency |
| Grace Healthcare Services Llc | Edison, NJ | Hospice |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optum Medical Care Of New Jersey Pc | 3072650290 | 231 |
News Archive
When the doors to the new Henry Ford West Bloomfield Hospital open March 15, patients, their families and the community will find a health care experience unlike any other, offering the latest in medicine, technology and patient safety, integrated with wellness and prevention programs all under one roof.
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.
ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.
President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.
Hollings Cancer Center researchers at the Medical University of South Carolina and colleagues assessed the connection between dietary advanced glycation end products and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.
› Verified 4 days ago
| Entity Name | Isaac J Dweck |
|---|---|
| Entity Type | Practitioner - Family Practice |
| Entity Identifiers | NPI Number: 1881785343 PECOS PAC ID: 3678462561 Enrollment ID: I20040310001211 |
News Archive
When the doors to the new Henry Ford West Bloomfield Hospital open March 15, patients, their families and the community will find a health care experience unlike any other, offering the latest in medicine, technology and patient safety, integrated with wellness and prevention programs all under one roof.
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.
ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.
President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.
Hollings Cancer Center researchers at the Medical University of South Carolina and colleagues assessed the connection between dietary advanced glycation end products and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.
› Verified 4 days ago
| Entity Name | Ocean Health Initiatives, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043306574 PECOS PAC ID: 2062405277 Enrollment ID: O20040405001022 |
News Archive
When the doors to the new Henry Ford West Bloomfield Hospital open March 15, patients, their families and the community will find a health care experience unlike any other, offering the latest in medicine, technology and patient safety, integrated with wellness and prevention programs all under one roof.
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.
ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.
President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.
Hollings Cancer Center researchers at the Medical University of South Carolina and colleagues assessed the connection between dietary advanced glycation end products and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.
› Verified 4 days ago
| Entity Name | Shore Health Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902944416 PECOS PAC ID: 0547254047 Enrollment ID: O20040408000832 |
News Archive
When the doors to the new Henry Ford West Bloomfield Hospital open March 15, patients, their families and the community will find a health care experience unlike any other, offering the latest in medicine, technology and patient safety, integrated with wellness and prevention programs all under one roof.
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.
ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.
President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.
Hollings Cancer Center researchers at the Medical University of South Carolina and colleagues assessed the connection between dietary advanced glycation end products and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.
› Verified 4 days ago
| Entity Name | Optum Medical Care Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578665048 PECOS PAC ID: 3072650290 Enrollment ID: O20091021000129 |
News Archive
When the doors to the new Henry Ford West Bloomfield Hospital open March 15, patients, their families and the community will find a health care experience unlike any other, offering the latest in medicine, technology and patient safety, integrated with wellness and prevention programs all under one roof.
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.
ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.
President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.
Hollings Cancer Center researchers at the Medical University of South Carolina and colleagues assessed the connection between dietary advanced glycation end products and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Terry K Brooks, NP-C 40 Monmouth Rd, Oakhurst, NJ 07755-1654 Ph: (732) 263-1220 | Mr Terry K Brooks, NP-C 40 Monmouth Rd, Oakhurst, NJ 07755-1654 Ph: (732) 263-1220 |
News Archive
When the doors to the new Henry Ford West Bloomfield Hospital open March 15, patients, their families and the community will find a health care experience unlike any other, offering the latest in medicine, technology and patient safety, integrated with wellness and prevention programs all under one roof.
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.
ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.
President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.
Hollings Cancer Center researchers at the Medical University of South Carolina and colleagues assessed the connection between dietary advanced glycation end products and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.
› Verified 4 days ago
Deborah Bader, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 40 Monmouth Rd, Oakhurst, NJ 07755 Phone: 732-522-4868 | |
Paula Graziano, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1907 State Route 35, Suite 1, Oakhurst, NJ 07755 Phone: 732-517-0060 Fax: 732-380-1965 | |
Caroline Leibowitz, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1907 Highway 35 Ste 1, Oakhurst, NJ 07755 Phone: 732-361-2476 | |
Mrs. Aileen Joanna Almeda Vasquez, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1912 Highway 35 Ste 201, Oakhurst, NJ 07755 Phone: 732-389-5004 Fax: 732-548-7408 | |
Andrea Wieder, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1910 Highway 35, Oakhurst, NJ 07755 Phone: 732-531-0100 Fax: 732-531-0144 | |
Lauren Sterling, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1910 Highway 35, Oakhurst, NJ 07755 Phone: 732-531-0100 | |
Ms. Inna Belenson, MSN, RN, APN-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1912 State Route 35, Suite 101, Oakhurst, NJ 07755 Phone: 732-222-4762 |